Keyword
Study

Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study in Glabellar Lines

Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy…